scholarly article | Q13442814 |
P50 | author | Zhihong Peng | Q57384124 |
Leticia I Llarrull | Q64514313 | ||
Mayland Chang | Q89378129 | ||
Katerina Zorina-Lichtenwalter | Q116455839 | ||
Malika Kumarasiri | Q118431448 | ||
Erika Leemans | Q118431699 | ||
Edward Spink | Q118431712 | ||
Derong Ding | Q118431724 | ||
Sebastian A Testero | Q118431740 | ||
Shahriar Mobashery | Q28316904 | ||
Mark A. Suckow | Q41543478 | ||
P2093 | author name string | Wei Song | |
Hualiang Pi | |||
Elena Lastochkin | |||
Marc A Boudreau | |||
Peter I O'Daniel | |||
Takao Yamaguchi | |||
Nuno T Antunes | |||
Valerie A Schroeder | |||
William R Wolter | |||
Mana Espahbodi | |||
Sergei Vakulenko | |||
P2860 | cites work | Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy | Q42708842 |
Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
Health care-associated invasive MRSA infections, 2005-2008. | Q44110236 | ||
The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus | Q44958662 | ||
A practical synthesis of nitrocefin | Q45206061 | ||
Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. | Q46878727 | ||
Inhibition of intracellular macromolecular synthesis in Staphylococcus aureus by thrombin-induced platelet microbicidal proteins. | Q53981730 | ||
Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus | Q59374940 | ||
The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) | Q24530652 | ||
Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus | Q27639852 | ||
ZINC--a free database of commercially available compounds for virtual screening | Q27656255 | ||
How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function | Q27680124 | ||
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin | Q28268465 | ||
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. | Q30228250 | ||
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors | Q33339829 | ||
Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway | Q33767185 | ||
Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 | Q33877838 | ||
Resistance studies with daptomycin | Q33982318 | ||
Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci | Q33982606 | ||
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity | Q33984936 | ||
Antibiotics: where did we go wrong? | Q36022317 | ||
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus | Q36381504 | ||
Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America | Q36382134 | ||
The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis | Q37081708 | ||
Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge. | Q37392891 | ||
BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins | Q39470055 | ||
Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus | Q39834475 | ||
P4510 | describes a project that uses | ImageQuant | Q112270642 |
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | gram-positive bacteria | Q857288 |
P1104 | number of pages | 9 | |
P304 | page(s) | 3664-3672 | |
P577 | publication date | 2014-02-21 | |
P1433 | published in | Journal of the American Chemical Society | Q898902 |
P1476 | title | Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity | |
P478 | volume | 136 |
Q64072509 | 1,2,4-Oxadiazole/2-Imidazoline Hybrids: Multi-target-directed Compounds for the Treatment of Infectious Diseases and Cancer |
Q40742571 | A Vancomycin Derivative with a Pyrophosphate-Binding Group: A Strategy to Combat Vancomycin-Resistant Bacteria |
Q58799329 | Activities of Oxadiazole Antibacterials against Staphylococcus aureus and Other Gram-Positive Bacteria |
Q51311450 | Computer-Aided Drug Design Methods. |
Q28821040 | Efficacy of ampicillin against methicillin-resistant Staphylococcus aureus restored through synergy with branched poly(ethylenimine) |
Q28822179 | Endless Resistance. Endless Antibiotics? |
Q36167152 | Exploration of the structure-activity relationship of 1,2,4-oxadiazole antibiotics |
Q26749531 | Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New Antibacterials |
Q33659793 | In Vitro Evaluations and In Vivo Toxicity and Efficacy Studies of MFM501 against MRSA. |
Q37203885 | In Vitro and In Vivo Synergy of the Oxadiazole Class of Antibacterials with β-Lactams |
Q92682023 | Ligands and Receptors with Broad Binding Capabilities Have Common Structural Characteristics: An Antibiotic Design Perspective |
Q38952894 | Membrane Disruption and Enhanced Inhibition of Cell-Wall Biosynthesis: A Synergistic Approach to Tackle Vancomycin-Resistant Bacteria. |
Q34298926 | Mutations in mmpL and in the cell wall stress stimulon contribute to resistance to oxadiazole antibiotics in methicillin-resistant Staphylococcus aureus |
Q50100988 | Novel bis-cyclic guanidines as potent membrane-active antibacterial agents with therapeutic potential. |
Q38712471 | One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams |
Q38232037 | Penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. |
Q60304005 | Reactions of 3-(-substituted-phenyl)-5-chloromethyl-1,2,4-oxadiazoles with KCN leading to acetonitriles and alkanes via a non-reductive decyanation pathway |
Q90412680 | Structure-Activity Relationship for the Oxadiazole Class of Antibacterials |
Q41543426 | Structure-activity relationship for the oxadiazole class of antibiotics. |
Q93013199 | Synergistic anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and absolute stereochemistry of 7,8-dideoxygriseorhodin C |
Q36248215 | Synthesis and evaluation of 1,2,4-triazolo[1,5-a]pyrimidines as antibacterial agents against Enterococcus faecium |
Q41686055 | Tackling vancomycin-resistant bacteria with 'lipophilic-vancomycin-carbohydrate conjugates'. |
Q49970485 | The FDA-approved anti-cancer drugs, streptozotocin and floxuridine, reduce the virulence of Staphylococcus aureus. |
Q39573499 | The Natural Product Essramycin and Three of Its Isomers Are Devoid of Antibacterial Activity |
Q38848065 | The oxadiazole antibacterials |
Q36848213 | Three-dimensional QSAR analysis and design of new 1,2,4-oxadiazole antibacterials |
Q38846432 | Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury |
Search more.